Prognostic value of systemic inflammation‐based markers in advanced pancreatic cancer

Abstract

Our findings suggest that the NLR, PLR and mGPS derived from routine blood tests can be used as clinically meaningful biomarkers to stratify advanced pancreatic cancer patients into different prognostic groups.